Supplier News: Catalent, Yposkesi, Enzene & More
The latest from CDMOs, CMOs, and suppliers featuring Catalent, Avantor, Curia, MilliporeSigma, Cytiva, Yposkesi, Enzene Biosciences, Andelyn Biosciences and Culture Biosciences.
General
* Catalent Names New CFO
* Avantor Launches Responsible Supplier Program
Biologics Manufacturing
* Yposkesi Inaugurates $65-M Cell- & Gene-Therapy Mfg Facility
* Enzene Biosciences Investing $50 M in New Biopharmaceutical Plant
* Andelyn Biosciences Opens New Mfg HQ for Cell & Gene Therapies
* Curia, MilliporeSigma in Licensing Pact for Cell-Line Platform
* Cytiva, Culture Biosciences Partner in Upstream Bioprocessing
General
Catalent Names New CFO
Catalent has named Matti Masanovich, formerly Executive Vice President & Chief Financial Officer (CFO) of Tenneco Automotive, as its Senior Vice President and CFO, effective July 5, 2023.
He takes on the role following the departure of the company’s former CFO, Thomas Castellano, Senior Vice President and CFO who stepped down, effective April 13, 2023, and who was replaced by Interim CFO, Ricky Hopson, who had been serving as the President and Division Head for Clinical Development & Supply at Catalent. The transitions in CFO followed business updates provided by the company that its fiscal third-quarter results would be delayed and that productivity issues and higher-than-expected costs experienced at three of its facilities would materially and adversely impact the company’s financial results for its fiscal third quarter (ending March 31, 2023). Earlier this month (June 2023), Catalent reported a $227-million loss in its fiscal third quarter on net revenue of $1.04 billion, a 19% decline (excluding the effect of acquisitions, divestitures, and currency translation) compared to the year-ago period.
Prior to joining Catalent, Masanovich served as Executive Vice President and CFO of Tenneco Automotive, an automobile company, until it was acquired by Apollo, a private-equity firm. Previous to that, he was CFO at Superior Industries International and General Cable Corporation, two manufacturing companies. Earlier in his career, Masanovich held finance leadership roles in a number of companies in the automotive industry. He began his career with PricewaterhouseCoopers.
Source: Catalent
Avantor Launches Responsible Supplier Program
Avantor, a distributor and supplier of products and services to the bio/pharmaceutical industry, has launched a Responsible Supplier Program, designed to help reduce environmental impact and accelerate sustainable practices across the supply chain. The program focuses on six priorities: climate change, deforestation, human rights, responsible packaging, waste, and water. These priorities were selected based on their relevance to Avantor and to suppliers’ businesses to enable collaboration with supplier partners to identify sustainability challenges and solutions.
Source: Avantor
Biologics Manufacturing
Yposkesi Inaugurates $65-M Cell- & Gene-Therapy Mfg Facility
Yposkesi, a CDMO of cell and gene therapies and a subsidiary of SK pharmteco, has inaugurated a new 5,000-square-meter industrial bioproduction site at its Genopole, France, campus with an investment of EUR 60 million ($65.3 million). The expansion doubles Yposkesi’s cGMP manufacturing footprint to 10,000 square meters and is Yposkesi’s second manufacturing facility in Genopole.
The new site, currently undergoing qualification, is scheduled to be fully operational in 2024 and will be equipped to run both adeno-associated vector and lentiviral platforms. The facility is designed with six upstream processing and two downstream processing cleanrooms. This more than triples Yposkesi’s bioreactor capacity from 2,000 L to 7,000 L and reduces the turnaround on projects from 18- to 12-months. It has fill–finish capacities with semi-automated suites for a total of 12,000 vials per year.
Source: Yposkesi
Enzene Biosciences Investing $50 M in New Biopharmaceutical Plant
Enzene Biosciences, a Pune, India-based CDMO of biologics, is investing $50 million into a biopharmaceutical plant in Hopewell, New Jersey. Operations in the new facility are expected to begin in June 2024. As part of Enzene’s expansion plans, the company will initially hire 50 employees and grow to 300 employees at its New Jersey facility. Enzene focuses on producing biosimilars, novel biologics, synthetic peptides, and phytopharmaceuticals.
Source: Choose New Jersey
Andelyn Biosciences Opens New Mfg HQ for Cell & Gene Therapies
Andelyn Biosciences, a Columbus, Ohio-based CDMO of cell and gene therapies, has opened a new manufacturing headquarters, the Andelyn Corporate Center, in Columbus, Ohio. The new facility has 180,000 square feet of office, laboratory, and manufacturing space and triples the company’s footprint. The new facility includes 16 cGMP modular manufacturing suites with upstream, downstream, solution preparation, and filling capabilities, along with quality control labs and warehouse and corporate headquarters space.
Source: Andelyn Biosciences
Curia, MilliporeSigma in Licensing Pact for Cell-Line Platform
Curia, a CDMO of drug substances and drug products, and MilliporeSigma, the life sciences business of Merck KGaA, have signed a licensing agreement that enables Curia and its clients to use MillioporeSigma’s CHOZN GS-/- cell line platform for production of therapeutic proteins and antibodies. The platform has been integrated into Curia’s cell-line development workflow. The platform is a Chinese hamster ovary (CHO) mammalian cell-line platform. It includes CHO cell lines, paired media and feeds, expression vectors, and protocols.
Source: Curia
Cytiva, Culture Biosciences Partner in Upstream Bioprocessing
Cytiva and Culture Biosciences, a South San Francisco, California-based biotechnology company, have entered a collaboration in upstream bioprocessing through scale-up capabilities. Under the collaboration, Cytiva’s bioreactor scaler tool now includes Culture’s 250-mL bioreactor. The bioreactor scaler tool enables scaling between development and manufacturing.
Source: Cytiva
